Speciality pharmaceutical developer Depomed (DEPO) says it's received a certification...

|About: Depomed Inc. (DEPO)|By:, SA News Editor

Speciality pharmaceutical developer Depomed (DEPO) says it's received a certification notification from Actavis Elizabeth, stating that it's filed an abbreviated new drug application with the FDA for a generic version of its Gralise in 300 mg and 600 mg tablets. Depomed in response has stated that it will "vigorously enforce" its intellectual property rights. Shares -3.6% AH.